A Startup Used AI to Make a Psychedelic Without the Trip

Although there is As growing evidence that psychedelic drugs can effectively treat serious mental health problems, especially in cases where traditional treatments have failed, they always come with drawbacks.

Their hallucinogenic effects can be frightening and overwhelming, with dosage sessions that last several hours. Good treatment strongly depends on the mentality of the individual in a session and the environment in which they receive it. And although it is rare, psychedelics can sometimes worsen existing mental illness.

Mindstate Design Labs is part of a list of new companies aimed at making safer psychedelics by removing the classic “journey” associated with them. The company uses AI to help design psychedelic drugs that induce specific mental states without hallucinations, and its first compound seems promising.

“We have created the least psychedelic psychedelic who is psychoactive,” explains CEO Dillan Dinardo. “It’s quite psychoactive, but there are no hallucinations.”

Founded in 2021 and supported by Y combinator and the founders of Openai, Neuralink, Instacart, Coinbase and Twitch, Mindstate has built a set of AI models which connect biochemical data from different psychactive drugs to more than 70,000 “travel reports” compiled from a variety of sources – Official Web and Official Clinical Datasets and Forums Social media, the variety of Reddit, and even the web.

The platform analysis of the way in which psychedellas produce different effects have led to the development of their first drug candidate, MSD-001, an oral formulation owner of 5-meo-Mipt, also known as rue Moxy. In the results of phase I trials shared with Wired, the drug was safe and well tolerated in different five doses in 47 healthy participants. He has also produced psychoactive effects without inducing a trap that folds, which, according to the company, is a validation of its AI platform.

While participants reported increased emotions, associative thought, improved imagination and perceptual effects such as brighter colors, they have not experienced hallucinations, self-disintegration, an ocean link and other characteristics typical of a psychedelic journey.

The company has measured the effects of the drug with validated scales used in psychedelic research and asked participants subjective such as “Are you happy?” And “Are you sad?” The researchers also observed the movement of the eyes and the stability of the volunteers, and they carried out brain imagery before, during and after the psychoactive effects. Using these brain imaging data, the company was able to determine that the drug produced many of the same brain waves models associated with psilocybine and other first generation psychedelics. “The drug enters the brain and does what we want it to do,” says Dinardo.

The psychoactive effects started within about 30 minutes after the participants took the medication, a peak intensity occurring about an hour and a half at two hours. The company does not report any serious adverse event.

The trial, which took place at the Center for Human Drug Research in the Netherlands, included a mixture of individuals who had tried psychedelics in the past and others who had not done so.

Mindstate’s approach is based on the idea that a psychedelic “journey” may not be necessary for a therapeutic benefit. Psychedelics work on the brain serotonin system by promoting neuroplasticity, which implies the growth of neurons and the formation of new connections. Some researchers believe that this ability to stimulate neuroplasticity, rather than hallucinogenic effects, is the key to the treatment of mental disease.